Phase 2 Type 1 Diabetes Trial, Recruiting NCT07224321 Sponsor: Mannkind Corporation Condition: Type 1 Diabetes
Back to Type 1 Diabetes

Phase 2 Type 1 Diabetes Trial, Recruiting

NCT07224321
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Be between 10 and 17 years old
  • Have been diagnosed with stage 3 Type 1 Diabetes (T1D), meaning blood sugar levels are high enough to meet standard diabetes diagnosis guidelines
  • Be able to start the study treatment within 21 days of their diabetes diagnosis (counting from the first insulin dose)
  • Have lung function test results showing the lungs are working at more than 80% of the expected level for their age and size
  • Be someone the study doctor believes can follow the study rules and schedule
  • Have no health conditions, mental health conditions, or current medications that the study doctor thinks would make participation unsafe

Who may not be able to join:

  • Have already received insulin treatment for an earlier stage (stage 2) of Type 1 Diabetes
  • Have a history of ongoing lung conditions such as asthma, chronic obstructive pulmonary disease (COPD), lung cancer, cystic fibrosis, or other significant lung diseases (confirm with trial site)
  • Have an allergy or known reaction to human regular insulin
  • Have smoked or vaped (including cigarettes, cigars, pipes, or marijuana) in the 3 months before screening, or test positive for a substance that shows recent smoking
  • Have a positive pregnancy test, if female and able to become pregnant

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 818-661-5032

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Mannkind Corporation
Registry
ClinicalTrials.gov
Start date
4 February 2026
Est. completion
1 March 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Percentage of participants with Continuous Glucose Meter (CGM) measured time in range (TIR) ≥70%

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov